HONG KONG, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Securities and Exchange Commission ("SEC") declared the Company's registration statement effective on February 9, 2010. The registration statement relates to the ordinary shares underlying warrants and certain other securities issued in connection with the initial public offering of Pantheon China Acquisition Corp.

As a result of the effectiveness, holders of public warrants issued and outstanding may now exercise them and receive ordinary shares upon the payment of the related exercise price.

If you have any questions regarding exercise procedures, please call your broker or Continental Stock Transfer & Trust at 212.509.4000 ext. 541.

About China Cord Blood Corporation

China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong). Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses have been issued as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information about China Cord Blood Corporation, please visit: http://www.chinacordbloodcorp.com .

    For more information, please contact:

    China Cord Blood Corporation

     Ms. Joeling Law
     Phone: +852-3605-8180
     Email: ir@chinacordbloodcorp.com

    ICR, Inc.

     In the United States:
     Ashley M. Ammon or Christine Duan
     Phone: +1-646-277-1200

     In China:
     Wei-Jung Yang
     Phone: +86-10-6599-7968

SOURCE China Cord Blood Corporation

Back to top